Kala Bio, Inc. (KALA)
0.1901
0.00 (0.00%)
USD |
NASDAQ |
Oct 23, 16:00
0.192
0.00 (0.00%)
After-Hours: 20:00
Kala Bio Enterprise Value : -3.552M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -3.552M |
| October 22, 2026 | -3.642M |
| October 21, 2026 | -3.539M |
| October 20, 2026 | -3.560M |
| October 19, 2026 | -3.504M |
| October 16, 2026 | -3.556M |
| October 15, 2026 | -3.512M |
| October 14, 2026 | -3.593M |
| October 13, 2026 | -2.201M |
| October 12, 2026 | -1.814M |
| October 09, 2026 | -1.544M |
| October 08, 2026 | -1.493M |
| October 07, 2026 | -0.2667M |
| October 06, 2026 | -0.1893M |
| October 05, 2026 | -0.2183M |
| October 02, 2026 | 0.2168M |
| October 01, 2026 | 0.8821M |
| September 30, 2026 | 1.074M |
| September 29, 2026 | 2.505M |
| September 28, 2026 | 1.478M |
| September 25, 2026 | 1.969M |
| September 24, 2026 | 3.601M |
| September 23, 2026 | 3.601M |
| September 22, 2026 | 4.356M |
| September 21, 2026 | 3.601M |
| Date | Value |
|---|---|
| September 18, 2026 | 3.195M |
| September 17, 2026 | 3.690M |
| September 16, 2026 | 2.859M |
| September 15, 2026 | 2.590M |
| September 14, 2026 | 3.228M |
| September 11, 2026 | 3.841M |
| September 10, 2026 | 3.657M |
| September 09, 2026 | 3.538M |
| September 08, 2026 | 3.174M |
| September 04, 2026 | 2.582M |
| September 03, 2026 | 3.621M |
| September 02, 2026 | 2.876M |
| September 01, 2026 | 3.064M |
| August 31, 2026 | 5.781M |
| August 28, 2026 | 6.117M |
| August 27, 2026 | 8.477M |
| August 26, 2026 | 8.554M |
| August 25, 2026 | 8.649M |
| August 24, 2026 | 8.154M |
| August 21, 2026 | 8.632M |
| August 20, 2026 | 9.018M |
| August 19, 2026 | 10.18M |
| August 18, 2026 | 10.15M |
| August 17, 2026 | 10.37M |
| August 14, 2026 | 11.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.581M |
| Total Expenses (Quarterly) | 1.581M |
| EPS Diluted (Quarterly) | -21.32 |
| Earnings Yield | -38.89K% |
| Normalized Earnings Yield | -51664.39 |